Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
EPIC: FARN
Market: AIM:FARN
52-week High/Low: 900.00p / 55.00p
Sector: Pharma & Biotech
Market Cap: 21.72M
Faron Pharmaceuticals Ltd (LON:FARN)

Faron Pharmaceuticals Ltd

Faron Pharmaceuticals is a clinical stage drug discovery and development company based in Turku, Finland. Faron has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. Implementing the strategy of creating a novel treatment for significant unmet medical needs, Faron has now entered into a pan-European pivotal Phase III study with...

Faron Pharmaceuticals Ltd

www.faronpharmaceuticals.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Faron Pharmaceuticals Ltd


Faron Pharmaceuticals Ltd Snapshot

Lean drug development company
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.

The Company's lead candidate Traumakine, to prevent vascular leakage and organ failures, is currently the only treatment for Acute Respiratory Distress Syndrome (ARDS) undergoing Phase III clinical trials. There is currently no approved pharmaceutical treatment for ARDS. An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (“RAAA”).

Faron’s second candidate Clevegen® is a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology ("TIET") may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients.

Faron operates in an agile way by sourcing its innovations primarily from academia. The inventors of the projects are close scientific collaborators with the Company and continue to be involved in further developments of the projects. As much of the development work up to the proof-of-concept stage can be contracted to the innovators’ labs, Faron is able to maintain a lean operating structure. As a result, Faron can run a relatively extensive drug development operation with significantly fewer members of staff and lower costs than would be possible for a typical drug development company.

Based in Turku, Finland, Faron Pharmaceuticals is listed in AIM under the ticker ‘FARN’.

Therapeutic areas
”Endothelial barrier is everything” - The endothelial surface of exhaustive capillary networks of central organs controls the fluid and cell balance between circulation and tissues. The endothelium is also a critical factor in many devastating diseases, such as organ failure and cancer metastasis. Faron’s pipeline is based on endothelial receptors involved in the regulation of immune responses and cell signalling.

Faron develops novel treatments for life-threatening medical conditions with significant unmet needs. Faron's core therapeutic areas are Acute Respiratory Syndrome (ARDS), organ protection and modulation of the immune system. To read more click here.

 

Traumakine (FP-1201-lyo)
Faron’s lead candidate, Traumakine® (FP-1201-lyo), is based on a patent-protected use of intra-venous interferon beta to prevent leakage of vascular beds in acute lung injuries. The active pharmaceutical ingredient in Traumakine® is recombinant human IFN beta-1a.

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Promising Innovative Medicines (PIM) designation for Traumakine®. The award of PIM designation is the first stage of the MHRA's Early Access Medicines Scheme (EAMS) and is granted when a medicine shows early signals, based on evidence to date, that it may be a possible candidate for the scheme. PIM designation under the EAMS also illustrates that a medicine has potential value in a disease area with significant and urgent unmet need and further qualifies an accompanying application and progression of the medicine towards the next stage in the EAMS process, which also allows early pricing negotiation with the UK National Institute for Health and Care Excellence (NICE).

Find out the Traumakine® mechanism of action, presented by Professor Geoff Bellingan, medical director at University College London Hospitals (UCLH), who led the Phase II trial. To read more please click here.

 

Clevegen (FP-1305)
One of Faron’s key areas of focus is to develop a cancer treatment to support the patients’ own immune defence against tumours, as these are often suppressed in cancer patients. Our second most advanced drug development project, Clevegen®, revolves around Clever-1, an endothelial cell surface molecule involved in cancer growth and spread. The active pharmaceutical ingredient of Clevegen® is an anti-Clever-1 antibody.

Clevegen can switch immune suppression to immune activation in various conditions: immune-oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology ("TIET") may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients.

Read more about the therapeutic areas and technologies we are exploring with Clevegen. To read more please cliick here.

 

Dr Markku Jalkanen
Chief Executive Officer & Founder

Over 25 years´ experience in biomedical research, biotech development and the biopharmaceutical industry

Former CEO of Biotie Therapies Corp., a NASDAQ-listed life science company. Adviser to Finnish life sciences fund, Inveni Capital

PhD in Medical Biochemistry and Docents in Biochemistry as well as Molecular and Cell Biology

 

Yrjö Wichmann
Chief Financial Officer

Over 20 years´ experience in financing and investment banking in the life science and biotechnology sector

Member of the Investment Committee at Dasos Timberland Fund I and II and the Innovation Board of Helsinki University which oversees the venture capital portfolio of Helsinki University Funds

Public company experience with London, Stockholm and Helsinki stock exchanges.

Master in Economics

 

Dr Juho Jalkanen
VP Business Development

Master´s degree in Economics and Business Administration from the Turku School of Economics, a Medical Doctor´s degree from the university of Turku, fully licensed General Practitioner, and Specialist in Vascular Surgery

Expert in organ protection during major cardiovascular surgery

Experienced in all aspects of the value chain of drug development from preclinical to translational and clinical studies, as well as market research and valuation of research projects and clinical programs

Manages Faron´s medical and business expansions

 

Dr Matti Karvonen
VP Drug Development, Chief Medical Officer

MD, PhD with a background in clinical neurology; holds also an eMBA

Solid medical experience in many international pharmaceutical organisations

Responsible for overseeing Faron´s drug development strategy and central role in expanding the clinical programmes of Traumakine® and Clevegen®

 

Dr Mikael Maksimow
VP Operations

Expert in autoimmune diseases and T cell biology

PhD in Molecular Medicine

Manages Faron´s operations, especially the vast vendor network

 

Dr Jami Mandelin
Research Director

PhD in Medical Biochemistry and Docent in Cell Biology

Expert in inflammation, immune response modulation and in immuno-oncology

Experience in medical organizations of international pharmaceutical industry

Manages Faron´s scientific network collaboration and pre-clinical drug development

 

Dr Juhana Heinonen
Chief Commercial Officer

PhD in Immunology, Karolinska Institutet, Stockholm, Sweden and MSc in Biochemistry, University of Turku, Finland

Pharmaceutical business executive, expertise in global marketing strategies and launches, track record of leading pharmaceutical business.

Previously worked in global marketing positions in AstraZeneca and Hoffmann La Roche.

Faron’s Chief Commercial Officer, directly responsible for the development and execution of a pre-launch and launch commercialisation strategy for Faron's drug candidates.

 

Dr Maria Lahtinen
Director, Supplier management

PhD in Medical Biochemistry and Docent in Cell Biology

Expert in inflammation, immune response modulation and in immuno-oncology

Experience in medical organizations of international pharmaceutical industry

Manages Faron´s scientific network collaboration and pre-clinical drug development

 

 

Faron Pharmaceuticals

Joukahaisenkatu 6, Intelligate
FI-20520 TURKU
Finland

Phone: +358 2 469 5151

Fax: +358 2 469 5152
Email: [email protected]

Nominated Adviser
Cairn Financial Advisers
Cheyne House, Crown Court
62-63 Cheapside
London EC2V 6AX

Broker
Panmure Gordon, Joint Broker
One New Change
London EC4M 9AF

Whitman Howard, Nominated Broker
First Floor
Connaught House
1-3 Mount Street
London W1K 3NB

Equity Adviser
RX Securities
Third Floor
1 Fore Street
Moorgatel
London EC2Y 9DT

Solicitors to the Company as to English law
Jones Day
21 Tudor Street
London EC4Y 0DY

Solicitors to the Company as to Finnish law
Hannes Snellman Attorneys Ltd
Eteläesplanadi 20
PO Box 333
00130/00131 Helsinki
Finland

Auditors to the Company
Pricewaterhouse Coopers Oy
P.O. Box 1015
Itämerentori 2
FI-00101 Helsinki
Finland

Public Relations
Hume Brophy
55 King William Street
London EC4R 9 AD

Depositary
Investor Services Plc
The Pavilions
Bridgwater Road
Bristol BS13 8AE

Finnish Registrar
Euroclear Finland Ltd
Urho Kekkosen katu 5C
Pl 1110, 00101 Helsinki
Finland

Faron Pharmaceuticals Ltd Timeline

RNS
June 15 2018
RNS
June 15 2018

Columns Including FARN

VIEW ALL

Market Reports Including FARN

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use